Center-Authored Papers

Filters: Author is Mlisana, Koleka  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
V
Volk JE, Hessol NA, Gray GE, Kublin JG, Churchyard GJ, Mlisana K, Nchabeleng M, Buchbinder SP, Bekker L-G.  2014.  The HVTN503/Phambili HIV vaccine trial: a comparison of younger and older participants.. International journal of STD & AIDS. 25(5):332-40. Abstract
M
Moodie Z, Metch B, Bekker L-G, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S, Mngadi K, Innes C et al..  2015.  Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.. PloS one. 10(9):e0137666. Abstract
L
Latka MH, Fielding K, Gray GE, Bekker L-G, Nchabeleng M, Mlisana K, Nielson T, Roux S, Mkhize B, Mathebula M et al..  2012.  Pregnancy incidence and correlates during the HVTN 503 Phambili HIV vaccine trial conducted among South African women.. PloS one. 7(4):e31387. Abstract
H
Hopkins KL, Laher F, Otwombe K, Churchyard G, Bekker L-G, De Rosa S, Nchabeleng M, Mlisana K, Kublin J, Gray G.  2014.  Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef Vaccine Induced Immune Responses.. PloS one. 9(8):e103446. Abstract
G
Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker L-G, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S et al..  2014.  Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.. The Lancet infectious diseases. 14(5):388-96. Abstract
Gray GE, Allen M, Moodie Z, Churchyard G, Bekker L-G, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH et al..  2011.  Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.. The Lancet infectious diseases. 11(7):507-15. Abstract
C
Churchyard G, Mlisana K, Karuna S, Williamson A-L, Williamson C, Morris L, Tomaras GD, De Rosa SC, Gilbert PB, Gu N et al..  2016.  Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants.. PloS one. 11(9):e0161753. Abstract